Ligand validation:8FSD

FFO: N-[4-({[(6S)-2-amino-5-formyl-4-oxo-3,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)benzoyl]-L-glutamic acid

FFO is a Ligand Of Interest in 8FSD designated by the Author

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
8FSD_FFO_A_508	72%	4%	0.108	0.932	4.15	1.65	13	6	0	0	100%	0.483
8FSD_FFO_C_508	72%	4%	0.12	0.943	4.11	1.64	14	5	1	0	100%	0.425
8FSD_FFO_B_808	32%	4%	0.179	0.853	4.16	1.53	13	4	2	0	100%	0.37
8FSD_FFO_D_708	31%	4%	0.181	0.847	4.17	1.67	14	6	1	0	100%	0.37
8DSK_FFO_C_502	85%	9%	0.088	0.953	2.79	1.71	12	6	0	0	100%	0.468
7TH4_FFO_B_303	95%	47%	0.076	0.98	0.96	1.1	2	2	0	0	100%	1
3UWL_FFO_B_316	79%	28%	0.103	0.95	1.18	1.68	3	5	2	0	100%	1
6R2E_FFO_E_403	76%	35%	0.124	0.96	0.94	1.59	1	4	5	0	100%	1
1PJ7_FFO_A_2887	68%	22%	0.103	0.915	1.46	1.79	3	10	0	0	100%	1

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM133198.